DNA & RNA Banking Services Market (2026 - 2033)

DNA & RNA Banking Services Market Summary

The global DNA & RNA banking services market size was valued at USD 8.3 billion in 2025 and is projected to grow from USD 8.8 billion in 2026 to USD 13.0 billion by 2033, at a CAGR of 5.7% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 38.0% in 2025. The increasing prevalence of genetic disorders and chronic diseases significantly contributes to the demand for DNA and RNA banking services.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

As genetic testing becomes more common for diagnosing and treating various medical conditions, the need to store genetic material for future use has surged. This trend is expected to drive the growth of the DNA & RNA banking services market as individuals seek to preserve their genetic information for potential healthcare needs.

Breakthroughs in genomics, including the development of CRISPR gene-editing technologies and next-generation sequencing, enhance the understanding of genetic information. These advancements drive greater demand for comprehensive genetic material storage, as researchers and clinicians require high-quality samples for innovative studies and treatments. Personalized medicine, which tailors healthcare strategies based on an individual’s genetic profile, is becoming more prevalent, increasing the need for secure and accessible DNA and RNA banks.

The expansion of biobanking infrastructure and technological innovations are key factors propelling the DNA and RNA banking services market. Advances in biobanking technologies, such as improved sample preservation methods and enhanced storage solutions, are making it easier and more cost-effective for organizations to manage and maintain genetic material. Developing sophisticated data management systems also allows for better organization, analysis, and retrieval of genetic information. These technological improvements support the scalability of DNA and RNA banking services and encourage more institutions to invest in biobanking infrastructure.

Analyst Perspective

The DNA & RNA banking services market is expected to witness sustained growth, driven by the expanding adoption of precision medicine, advancements in genomic research, and the growing demand for genetic testing across clinical and research applications. The increasing utilization of genetic testing services, expansion of biobanking programs, and rising demand for high-quality biological specimens are fueling the need for reliable DNA and RNA preservation, storage, and management services. In addition, continuous advancements in sample storage technologies, automation, and next-generation sequencing capabilities are improving the long-term integrity and accessibility of biological specimens.

Furthermore, growing applications in drug discovery, biomarker research, and personalized medicine are creating new opportunities for market participants. Increasing investments in precision healthcare initiatives, translational research, and large-scale population genomics projects are expected to further accelerate the adoption of DNA & RNA banking services worldwide throughout the forecast period.

Services Insights

The storage service segment dominated the market, accounting for about 36.5% of revenue in 2025. As personalized medicine evolves, there is a growing need to securely store vast amounts of genetic data. This trend is pushing healthcare providers, research institutions, and biotechnology companies to invest in advanced storage solutions that ensure the integrity and accessibility of genetic material for future diagnostic and therapeutic innovations.

The quality control services segment is anticipated to register the fastest CAGR over the forecast period. Agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies have established stringent guidelines for the handling, storage, and quality of genetic materials used in research and clinical applications. These regulations demand rigorous Quality Control (QC) procedures to ensure that DNA and RNA samples are uncontaminated, correctly labeled, and stored under optimal conditions to maintain their integrity.

Specimen Insights

The blood specimen type accounted for the largest share of market revenue in 2025. The rising prevalence of genetic disorders and chronic diseases, with conditions such as cancer, cardiovascular diseases, and rare genetic disorders, often requires genetic testing for diagnosis, management, and treatment planning. Blood samples provide essential genetic material for detecting genetic mutations, understanding disease mechanisms, and developing targeted therapies.

The buccal swabs & hair follicles segment is anticipated to register the fastest CAGR over the forecast period. Advancements in DNA extraction and analysis technologies, such as improved isolation methods and more sensitive analysis technologies, have enhanced the quality and yield of genetic material obtained from buccal swabs and hair follicles. Technologies such as high-throughput sequencing and advanced PCR methods enable more efficient and accurate genetic analysis of these specimen types.

Application Insights

The drug discovery & clinical research accounted for the largest market revenue share in 2025. The increasing adoption of precision medicine approaches, integrating genomic data into clinical decision-making, drives demand for high-quality genetic material stored in biobanks. Researchers can uncover valuable insights from DNA and RNA samples that inform personalized treatment strategies by leveraging advanced sequencing technologies and bioinformatics tools.

The therapeutics segment is anticipated to register the fastest CAGR over the forecast period. The expanding applications of DNA and RNA-based therapeutics, including gene editing, gene therapy, and mRNA-based vaccines, play a pivotal role in fostering market growth. As these innovative therapeutic modalities continue to gain traction in the healthcare industry, there is a heightened demand for high-quality genetic material for research, clinical trials, and commercialization. This has led to an increased reliance on DNA and RNA banking services to provide a reliable supply of genetic samples for the development of cutting-edge therapeutics, thus fueling the growth of this segment within the market.

End Use Insights

The academic research segment dominated the market in 2025. Government agencies, private foundations, and international organizations invest in genomic research to advance our understanding of genetics, uncover new disease mechanisms, and develop innovative treatments. For instance, in March 2025, Tecnológico de Monterrey (Tec de Monterrey) and The University of Texas at Austin jointly launched the OriGen Health Research Center, the first cross-border health research center to leverage data from Latin America's largest biobank for precision medicine research. According to the institutions, the center will conduct advanced research on chronic diseases affecting Latino populations by using genetic and clinical data from the OriGen biobank, with the aim of accelerating discoveries in precision medicine.

The hospitals & diagnostic centers segment is anticipated to register the fastest CAGR over the forecast period. Hospitals and diagnostic centers are increasingly offering specialized genetic tests for chronic conditions like cancer, cardiovascular diseases, and metabolic disorders, as well as for rare genetic disorders that require precise genetic information for diagnosis and management. As the healthcare industry emphasizes identifying genetic markers for these conditions, there is a growing need for a diverse collection of DNA and RNA specimens.

Regional Insights

North America's DNA & RNA banking services market accounted for the largest revenue share, at approximately 38.0%, in 2025. North America focuses on integrating genetic testing into clinical practice to develop personalized treatment plans, improve patient outcomes, and predict disease risks. This shift towards customized medicine increases the need for comprehensive DNA and RNA banking services to support genetic testing, research, and the development of targeted therapies. Hospitals, diagnostic centers, and research institutions in North America are expanding their genetic testing capabilities, which drives the growth of the DNA & RNA banking services market.

To learn more about this report, Download Free Sample Report

Asia Pacific DNA & RNA Banking Services Market Trends

The Asia Pacific DNA & RNA banking services market is anticipated to register the fastest CAGR over the forecast period. Countries such as China, India, and Japan invest heavily in genomics to drive advances in personalized medicine, cancer research, and rare disease research. For instance, China’s National Genomics Data Center (NGDC) and the Chinese Academy of Sciences are leading initiatives to build large-scale genomic databases and to promote innovative genomics research. Similarly, India’s Department of Biotechnology has funded several projects focusing on genomics and bioinformatics. These investments foster the development of new technologies and methodologies, which drive the demand for DNA and RNA banking services to support various research initiatives and clinical applications.

Europe DNA & RNA Banking Services Market Trends

Europe DNA & RNA banking services market was identified as a lucrative region in 2025. European countries are progressively integrating genetic information into clinical practice to provide personalized treatment plans, predict disease risks, and tailor preventive strategies. Initiatives such as the European Genomic Medicine Consortium aim to leverage genetic data for customized patient care and population health studies. The European Commission's Horizon Europe program continues to fund research collaboration in personalized and genomic medicine, advancing the field of precision medicine by investing in genomics and biobanking.

The UK DNA & RNA banking services market is expected to grow rapidly in the coming years. The UK has seen an increased focus on identifying and treating rare diseases through initiatives such as the Rare Disease Framework, which aims to improve diagnosis, treatment, and care for individuals with rare conditions. Genetic testing is crucial for diagnosing these conditions and understanding their genetic underpinnings. Additionally, the increasing prevalence of chronic diseases like cancer, cardiovascular diseases, and diabetes has led to greater use of genetic tests for early detection and management of these conditions. This growing demand for genetic testing drives the need for robust DNA and RNA banking services to support research and diagnostic efforts.

Key DNA & RNA Banking Services Company Insights

The Key companies in the DNA & RNA Banking Services market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions and partnerships with other major companies. Some of the key companies in the DNA & RNA banking services market include EasyDNA, DNA Genotek Inc., GoodCell, Infinity Biologix, and others.

Key DNA & RNA Banking Services Companies

The following key companies have been profiled for this study on the DNA & RNA banking services market:

• EasyDNA

• DNA Genotek Inc.

• GoodCell

• ProteoGenex

• Infinity Biologix

• Thermo Fisher Scientific, Inc.

• deCODE genetics

• Brooks Life Sciences

• PreventionGenetics

Recent Developments

• In July 2025, the Ministry of Science & Technology inaugurated the Phenome India National Biobank at the CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB). According to the official announcement, the biobank is designed to collect and maintain genomic, lifestyle, and clinical data from approximately 10,000 individuals to support long-term health research, disease understanding, and precision medicine initiatives.

• In May 2025, Astoriom expanded its sample stability storage capacity at its Tramore, Ireland, facility to address the growing demand from customers for regulatory-compliant storage solutions. The expansion strengthened the company’s cryogenic storage capabilities and increased its network of validated storage facilities.

• In April 2025, Sapio Sciences launched its Biorepository Management solution as part of Sapio Release 25.4. The solution enables centralized management of biospecimen workflows across multiple sites, including sample registration, storage, tracking, preparation, shipment, and request management. According to the company, the solution is designed to support biobanks, genomics research, clinical trials, and personalized medicine applications.

Global DNA & RNA Banking Services Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global DNA & RNA banking services market report based on service, specimen, application, end use, and region:

• Service Outlook (Revenue, USD Billion, 2021 - 2033)
  • Transportation Service
  • Processing Service
  • Storage Service
  • Quality Control Service
  • Data Storage
  • Others
• Specimen Outlook (Revenue, USD Billion, 2021 - 2033)
  • Blood
  • Buccal Swabs & Hair Follicles
  • Others
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Therapeutics
  • Drug Discovery & Clinical Research
  • Clinical Diagnostics
  • Other Applications
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Academic Research
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Diagnostic Centers
  • Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Kuwait